Using Inotuzumab Ozogamicin to treat adults with a specific type of leukemia after initial chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial evaluates the efficacy and safety of Inotuzumab Ozogamicin in adult patients diagnosed with B-cell Acute Lymphocytic Leukemia (B-ALL) who have achieved hematologic complete remission but remain positive for minimal residual disease after first-line induction chemotherapy. The study is a single-center, single-arm, open-label design, focusing on patients with a specific molecular disease threshold. Participants will receive Inotuzumab Ozogamicin to assess its effectiveness in eliminating residual leukemia cells.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. New diagnosed B-ALL in hematologic complete remission (CR) after 1L induction chemotherapy with MRD positive. Molecular disease or MRD is defined by a value of at least of 10-4 (0.01%) by multicolor flow cytometry.
2. Age ≥18 years
3. ECOG PS score: 0 to 2
4. Functions of the main organs are normal, if the following criteria are met:

   1. Total bilirubin (BIL) ≤ 1.5 × upper limit of normal (ULN)
   2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN
   3. Serum creatinine ≤ 1.5 × ULN
   4. Creatinine clearance ≥ 30 ml/min
5. No active or co-existing malignancy with a life expectancy of less than 12 months
6. Patients are voluntarily enrolled into the study and have good compliance, and the Informed Consent Form (ICF) needs to be signed.

Exclusion Criteria:

1. Mixed lineage leukemia
2. Clinically significant liver disease such as history of veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS)
3. Patients with severe and / or uncontrolled diseases, such as:

   1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmias; uncontrolled blood pressure (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg)
   2. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis
   3. Known to be human immunodeficiency virus positive (HIV+)
   4. Active and uncontrolled disease/infection as judged by the treating physician
   5. Active central nervous system (CNS) or extramedullary disease
   6. Patients who have other malignant tumors at the same time; patients who are evaluated by the investigator to have concomitant diseases that seriously endanger the safety of the patients or affect the patients to complete the study
4. Pregnant or nursing women
5. Unable or unwilling to sign the consent form
6. Monoclonal antibodies therapy within 2 weeks before study entry
7. Radiotherapy or cancer chemotherapy (except for induction chemo) or any investigational drug within 2 weeks before study entry
8. Patients who have severe allergies (≥ grade 3) to active ingredients and any excipients of InO
9. Patients in other situations who are evaluated by the investigator to be ineligible

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Tianjin, Tianjin, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCOR and ZC3H12 gene‑knockout CD19 CAR‑T therapy for adults with relapsed/refractory B‑cell ALL

  This will test whether autologous CD19‑targeting CAR‑T cells with BCOR and ZC3H12 genes knocked out can be safe and produce durable remissions in adults with relapsed or refractory B‑cell acute lymphoblastic leukemia.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Biotherapeutic Department of Chinese PLA General Hospital and 1 other locations · NCT07008885

• Combining an unmodified family (haplo‑identical) donor graft with cord blood for transplant

  This trial will test whether giving an unmodified haplo‑identical donor graft followed by a cord blood graft with post‑transplant cyclophosphamide helps people with high‑risk AML, ALL, or MDS stay free of disease.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06904482

• New CAR-T therapy with IL-15 for treating blood cancers

  This study is testing a new CAR-T therapy combined with IL-15 to see if it can help people with blood cancers like leukemia and multiple myeloma.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT06783816

• Gene Knock-out CAR-T Cell Therapy for Acute Lymphocytic Leukemia

  This study is testing a new type of CAR-T cell therapy to see if it can help people with hard-to-treat B-cell acute lymphoblastic leukemia feel better and fight their cancer.

  Recruiting at 5 sites Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality and 5 other locations · NCT06481735

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.